189 related articles for article (PubMed ID: 24675038)
1. Feasibility of pegylated interferon and ribavirin in hepatitis C-related cirrhosis with neutropenia or thrombocytopenia.
Iacobellis A; Cozzolongo R; Minerva N; Valvano MR; Niro GA; Fontana R; Palmieri O; Ippolito A; Andriulli A
Dig Liver Dis; 2014 Jul; 46(7):621-4. PubMed ID: 24675038
[TBL] [Abstract][Full Text] [Related]
2. Predictors of severe haematological toxicity secondary to pegylated interferon plus ribavirin treatment in HIV-HCV-coinfected patients.
Mira JA; López-Cortés LF; Merino D; Arizcorreta-Yarza A; Rivero A; Collado A; Ríos-Villegas MJ; González-Serrano M; Torres-Tortoso M; Macías J; Valera-Bestard B; Fernández-Fuertes E; Girón-González JA; Lozano F; Pineda JA;
Antivir Ther; 2007; 12(8):1225-35. PubMed ID: 18240862
[TBL] [Abstract][Full Text] [Related]
3. Incident severe thrombocytopenia in veterans treated with pegylated interferon plus ribavirin for chronic hepatitis C infection.
Hermos JA; Quach L; Gagnon DR; Weber HC; Altincatal A; Cho K; Lawler EV; Grotzinger KM
Pharmacoepidemiol Drug Saf; 2014 May; 23(5):480-8. PubMed ID: 24677630
[TBL] [Abstract][Full Text] [Related]
4. Incidence and predictors of hematological side effects in chronic HCV Egyptian patients treated with PEGylated interferon and ribavirin.
Lashin AH; Shaheen YA; Metwally MA; El-Feky HM; Hegab MF; Abbas SM
Indian J Gastroenterol; 2013 Sep; 32(5):316-23. PubMed ID: 23715642
[TBL] [Abstract][Full Text] [Related]
5. Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy.
Afdhal NH; Dusheiko GM; Giannini EG; Chen PJ; Han KH; Mohsin A; Rodriguez-Torres M; Rugina S; Bakulin I; Lawitz E; Shiffman ML; Tayyab GU; Poordad F; Kamel YM; Brainsky A; Geib J; Vasey SY; Patwardhan R; Campbell FM; Theodore D
Gastroenterology; 2014 Feb; 146(2):442-52.e1. PubMed ID: 24126097
[TBL] [Abstract][Full Text] [Related]
6. Cirrhosis but not neutropenia is associated with the development of infection in patients with chronic hepatitis C undergoing treatment with pegylated interferon-alpha and ribavirin.
Striki A; Manolakopoulos S; Deutsch M; Mela M; Kalafateli M; Schini M; Anagnostou O; Triantos C; Andreadis I; Ketikoglou I; Papatheodoridis G; Pectasides D
J Viral Hepat; 2014; 21(9):624-32. PubMed ID: 24224747
[TBL] [Abstract][Full Text] [Related]
7. The study of relationship between neutropenia and infection during treatment with peginterferon α and ribavirin for chronic hepatitis C.
Yu JW; Sun LJ; Zhao YH; Kang P; Yan BZ
Eur J Gastroenterol Hepatol; 2011 Nov; 23(12):1192-9. PubMed ID: 21971375
[TBL] [Abstract][Full Text] [Related]
8. Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin.
Antonini MG; Babudieri S; Maida I; Baiguera C; Zanini B; Fenu L; Dettori G; Manno D; Mura MS; Carosi G; Puoti M
Infection; 2008 Jun; 36(3):250-5. PubMed ID: 18458815
[TBL] [Abstract][Full Text] [Related]
9. Incidence and severity of infections according to the development of neutropenia during combined therapy with pegylated interferon-alpha2a plus ribavirin in chronic hepatitis C infection.
Juarez-Navarro A; Vera-de-León L; Navarro JM; Chirino-Sprung R; Díaz-Hernandez M; Casillas-Davila L; Dehesa-Violante M
Methods Find Exp Clin Pharmacol; 2005 Jun; 27(5):317-22. PubMed ID: 16082419
[TBL] [Abstract][Full Text] [Related]
10. Risk of infections during interferon-based treatment in patients with chronic hepatitis C virus infection and advanced hepatic fibrosis.
Maan R; van der Meer AJ; Hansen BE; Feld JJ; Wedemeyer H; Dufour JF; Lammert F; Manns MP; Zeuzem S; Janssen HL; de Knegt RJ; Veldt BJ
J Gastroenterol Hepatol; 2015 Jun; 30(6):1057-64. PubMed ID: 25682797
[TBL] [Abstract][Full Text] [Related]
11. Cytopenias during treatment of HIV-HCV-coinfection with pegylated interferon and ribavirin: safety analysis of the OPERA study.
Pontali E; Angeli E; Cattelan AM; Maida I; Nasta P; Verucchi G; Caputo A; Iannacone C; Puoti M
Antivir Ther; 2015; 20(1):39-48. PubMed ID: 24831457
[TBL] [Abstract][Full Text] [Related]
12. Thrombocytopenia and the risk of bleeding during treatment with peginterferon alfa and ribavirin for chronic hepatitis C.
Roomer R; Hansen BE; Janssen HL; de Knegt RJ
J Hepatol; 2010 Sep; 53(3):455-9. PubMed ID: 20561709
[TBL] [Abstract][Full Text] [Related]
13. Severe thrombocytopenia in a patient with inosine triphosphatase (ITPA)-CC genotype caused by pegylated interferon (IFN)-α-2a with ribavirin therapy: a case report.
Jiang W; Hidaka H; Nakazawa T; Kitagawa H; Koizumi W
BMC Res Notes; 2014 Mar; 7():141. PubMed ID: 24621321
[TBL] [Abstract][Full Text] [Related]
14. Modifications of haematological series in patients co-infected with human immunodeficiency virus and hepatitis C virus during treatment with interferon and ribavirin: differences between pegylated and standard interferon.
Arizcorreta A; Brun F; Fernández-Gutiérrez C; García Juárez R; Guerrero F; Pérez-Guzmán E; Girón-González JA
Clin Microbiol Infect; 2004 Dec; 10(12):1067-74. PubMed ID: 15606633
[TBL] [Abstract][Full Text] [Related]
15. [Side-effects of pegylated interferon plus ribavirin therapy with or without protease inhibitor direct acting antiviral agents during treatment of chronic hepatitis C virus infection].
Hunyady B; Kovács B; Battyáni Z
Orv Hetil; 2011 Dec; 152(50):1997-2009. PubMed ID: 22112373
[TBL] [Abstract][Full Text] [Related]
16. [Clinical efficacy and safety of the combination therapy of peginterferon alpha and ribavirin in cirrhotic patients with HCV infection].
Cheong HR; Woo HY; Heo J; Yoon KT; Kim DU; Kim GH; Kang DH; Song GA; Cho M
Korean J Hepatol; 2010 Mar; 16(1):38-48. PubMed ID: 20375641
[TBL] [Abstract][Full Text] [Related]
17. Risk factors for infection during treatment with peginterferon alfa and ribavirin for chronic hepatitis C.
Roomer R; Hansen BE; Janssen HL; de Knegt RJ
Hepatology; 2010 Oct; 52(4):1225-31. PubMed ID: 20830784
[TBL] [Abstract][Full Text] [Related]
18. Prognostic effect of response to interferon therapy after laparoscopic splenectomy among patients with marked thrombocytopenia and hepatitis C virus-related cirrhosis.
Tamai H; Mori Y; Shingaki N; Shimizu R; Nuta J; Moribata K; Maeda Y; Muraki Y; Deguchi H; Inoue I; Maekita T; Iguchi M; Kato J; Takifuji K; Yamaue H; Ichinose M
Hepatol Int; 2015 Jan; 9(1):67-75. PubMed ID: 25788381
[TBL] [Abstract][Full Text] [Related]
19. Effect of thrombocytopenia on treatment tolerability and outcome in patients with chronic HCV infection and advanced hepatic fibrosis.
Maan R; van der Meer AJ; Hansen BE; Feld JJ; Wedemeyer H; Dufour JF; Zangneh HF; Lammert F; Manns MP; Zeuzem S; Janssen HL; de Knegt RJ; Veldt BJ
J Hepatol; 2014 Sep; 61(3):482-91. PubMed ID: 24780302
[TBL] [Abstract][Full Text] [Related]
20. Review article: optimizing SVR and management of the haematological side effects of peginterferon/ribavirin antiviral therapy for HCV - the role of epoetin, G-CSF and novel agents.
Mac Nicholas R; Norris S
Aliment Pharmacol Ther; 2010 May; 31(9):929-37. PubMed ID: 20175767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
